Matches in DBpedia 2016-04 for { ?s ?p "Mitumomab (BEC-2) is a mouse monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. As of September 2009, the drug is undergoing Phase III clinical trials."@en }
Showing triples 1 to 4 of
4
with 100 triples per page.
- Mitumomab abstract "Mitumomab (BEC-2) is a mouse monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. As of September 2009, the drug is undergoing Phase III clinical trials.".
- Q6883597 abstract "Mitumomab (BEC-2) is a mouse monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. As of September 2009, the drug is undergoing Phase III clinical trials.".
- Mitumomab comment "Mitumomab (BEC-2) is a mouse monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. As of September 2009, the drug is undergoing Phase III clinical trials.".
- Q6883597 comment "Mitumomab (BEC-2) is a mouse monoclonal antibody investigated for the treatment of small cell lung carcinoma in combination with BCG vaccination. Mitumomab attacks tumour cells, while the vaccine is thought to activate the immune system. As of September 2009, the drug is undergoing Phase III clinical trials.".